Is the combination of linagliptin and allopurinol better prophylaxis against post-contrast acute kidney injury? A multicenter prospective randomized controlled study

Document Type : Abstracts

Abstract

Patients with diabetic kidney disease (DKD) are at increased risk of developing postcontrast acute kidney injury (AKI). Diabetic patients under dipeptidyl peptidase 4 inhibitors (DPP4Is) experience a lower propensity to develop AKI. We speculated that linaglipin as a single agent or in combination with allopurinol may reduce the incidence of post-contrast AKI in stage 3–5 chronic kidney disease (CKD) patients with underlying DKD. 
Egyptian Society of Diabetes and Lipidology Journal
Volume 3, Issue 2
October 2023

Files

Share

How to cite

Statistics